|
Jan 24
|
Pharma Stock Roundup: JNJ's Q4 Earnings, FDA Nod to AZN, Daiichi Drug
|
|
Jan 24
|
Alphabet, Uber, Applied Materials, and 19 Other Picks From the Barron’s Roundtable
|
|
Jan 24
|
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
|
|
Jan 4
|
Better Buy: Novo Nordisk vs. AstraZeneca
|
|
Jan 3
|
China’s NMPA prioritises HUTCHMED’s lung cancer therapy review
|
|
Jan 3
|
The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer
|
|
Jan 2
|
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN
|
|
Jan 2
|
5 Large Drug Stocks to Keep An Eye On in the New Year
|
|
Dec 30
|
Is AstraZeneca PLC (AZN) Among the U.K. Dividend Champions for 2024?
|
|
Dec 29
|
Is AstraZeneca PLC (AZN) Among the U.K. Dividend Aristocrats for 2024?
|
|
Dec 15
|
3 Unstoppable Stocks to Buy Right Now
|
|
Dec 12
|
Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study
|
|
Dec 11
|
AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients
|
|
Dec 11
|
LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial
|
|
Dec 10
|
AstraZeneca’s (AZN) Struggles: Cramer’s Disappointment and Challenges in China
|
|
Dec 10
|
AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC
|
|
Dec 10
|
Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term
|
|
Dec 9
|
Astrazeneca Reports Positive Phase 3 Calquence Data for Chronic Lymphocytic Leukemia
|
|
Dec 9
|
AZN's Bladder Cancer sBLA for Imfinzi Gets FDA's Priority Tag
|
|
Dec 9
|
Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
|